-
1.发明授权Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging 有权等离子体化合物，含有其的药物组合物和治疗老化疾病的方法公开(公告)号：US09334235B2
公开(公告)日：2016-05-10
申请号：US13141035
申请日：2009-12-18
IPC分类号： C07C229/22 , C07C323/59 , C07C279/14 , C07D339/04 , C07F9/10
CPC分类号： C07C323/59 , C07C229/22 , C07C279/14 , C07D339/04 , C07F9/106
摘要： Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).
摘要翻译： 本文描述了式I的1-烷基，2-酰基甘油衍生物的合成途径和治疗用途：当向哺乳动物生物系统施用时，其导致独特于醚脂质合成能力的特异性sn-2取代的乙醇胺plasmalogen的细胞浓度增加 的系统。 以这种方式提高特定sn-2取代物种的水平可能导致膜胆固醇水平的降低和淀粉样蛋白分泌的降低。 这些化合物可用于治疗或预防与增加的膜胆固醇，增加的淀粉样蛋白相关的老化疾病和降低的血浆素水平，例如神经变性（包括阿尔茨海默病，帕金森病和年龄相关性黄斑变性），认知障碍，痴呆 ，癌症（例如前列腺癌，肺癌，乳腺癌，卵巢癌和肾癌），骨质疏松症，双相性精神障碍和血管疾病（如动脉粥样硬化，高胆固醇血症）。
-
2.发明申请PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF THE AGING 有权等离子体化合物，含有它们的药物组合物和治疗老化疾病的方法公开(公告)号：US20120035250A1
公开(公告)日：2012-02-09
申请号：US13141035
申请日：2009-12-18
IPC分类号： A61K31/232 , C07C69/587 , C07C227/18 , C07D339/04 , C07C231/12 , C07C233/47 , A61P25/28 , A61P25/16 , A61P27/02 , C07C229/30 , A61K31/385
CPC分类号： C07C323/59 , C07C229/22 , C07C279/14 , C07D339/04 , C07F9/106
摘要： Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).
摘要翻译： 本文描述了式I的1-烷基，2-酰基甘油衍生物的合成途径和治疗用途：当向哺乳动物生物系统施用时，其导致独特于醚脂质合成能力的特异性sn-2取代的乙醇胺plasmalogen的细胞浓度增加 的系统。 以这种方式提高特定sn-2取代物种的水平可能导致膜胆固醇水平的降低和淀粉样蛋白分泌的降低。 这些化合物可用于治疗或预防与增加的膜胆固醇，增加的淀粉样蛋白相关的老化疾病和降低的血浆素水平，例如神经变性（包括阿尔茨海默病，帕金森病和年龄相关性黄斑变性），认知障碍，痴呆 ，癌症（例如前列腺癌，肺癌，乳腺癌，卵巢癌和肾癌），骨质疏松症，双相性精神障碍和血管疾病（如动脉粥样硬化，高胆固醇血症）。
-
搜索结果
2 条记录 (耗时 0.028 秒)
